-
1
-
-
2542561964
-
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
-
Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
-
(2004)
N Engl J Med
, vol.350
, pp. 2335-2342
-
-
Hurwitz, H.1
Fehrenbacher, L.2
Novotny, W.3
-
2
-
-
38449100932
-
Anti-vascular endothelial growth factor therapy for ocular neovascular disease
-
Andreoli CM, Miller JW. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol. 2007;18:502-508.
-
(2007)
Curr Opin Ophthalmol
, vol.18
, pp. 502-508
-
-
Andreoli, C.M.1
Miller, J.W.2
-
3
-
-
0023693837
-
An animal model for corneal graft rejection in highrisk keratoplasty
-
Hill JC, Maske R. An animal model for corneal graft rejection in highrisk keratoplasty. Transplantation. 1988;46:26-30.
-
(1988)
Transplantation
, vol.46
, pp. 26-30
-
-
Hill, J.C.1
Maske, R.2
-
4
-
-
34548279498
-
Safety profile of bevacizumab on cultured human corneal cells
-
Yoeruek E, Spitzer MS, Tatar O, et al. Safety profile of bevacizumab on cultured human corneal cells. Cornea. 2007;26:977-982.
-
(2007)
Cornea
, vol.26
, pp. 977-982
-
-
Yoeruek, E.1
Spitzer, M.S.2
Tatar, O.3
-
5
-
-
79955957252
-
Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro
-
O'Neill EC, Qin Q, Van Bergen NJ, et al. Antifibrotic activity of bevacizumab on human Tenon's fibroblasts in vitro. Invest Ophthalmol Vis Sci. 2010;51:6524-6532.
-
(2010)
Invest Ophthalmol Vis Sci
, Issue.51
, pp. 6524-6532
-
-
O'Neill, E.C.1
Qin, Q.2
Van Bergen, N.J.3
-
6
-
-
0033856243
-
Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas
-
Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41:2514-2522.
-
(2000)
Invest Ophthalmol Vis Sci
, vol.41
, pp. 2514-2522
-
-
Philipp, W.1
Speicher, L.2
Humpel, C.3
-
7
-
-
44449119809
-
The effect of topical bevacizumab on corneal neovascularization
-
Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization. Ophthalmology. 2008;115:e33-e38.
-
(2008)
Ophthalmology
, vol.115
-
-
Kim, S.W.1
Ha, B.J.2
Kim, E.K.3
-
8
-
-
77952550711
-
Corneal melt while using topical bevacizumab eye drops
-
Galor A, Yoo SH. Corneal melt while using topical bevacizumab eye drops. Ophthalmic Surg Lasers Imaging. 2010;41:1-3.
-
(2010)
Ophthalmic Surg Lasers Imaging
, Issue.41
, pp. 1-3
-
-
Galor, A.1
Yoo, S.H.2
-
9
-
-
0028827625
-
Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo
-
Asahara T, Bauters C, Zheng LP, et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation. 1995;92(9 suppl):II365-II371.
-
(1995)
Circulation
, vol.92
, Issue.9 SUPPL.
-
-
Asahara, T.1
Bauters, C.2
Zheng, L.P.3
-
10
-
-
10644279947
-
Vascular endothelial growth factor and angiogenesis
-
Hoeben A, Landuyt B, Highley MS, et al. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004;56:549-580.
-
(2004)
Pharmacol Rev
, vol.56
, pp. 549-580
-
-
Hoeben, A.1
Landuyt, B.2
Highley, M.S.3
-
12
-
-
44349149183
-
Regulation of scar formation by vascular endothelial growth factor
-
Wilgus TA, Ferreira AM, Oberyszyn TM, et al. Regulation of scar formation by vascular endothelial growth factor. Lab Invest. 2008;88:579-590.
-
(2008)
Lab Invest
, vol.88
, pp. 579-590
-
-
Wilgus, T.A.1
Ferreira, A.M.2
Oberyszyn, T.M.3
-
13
-
-
53149126121
-
Vascular endothelial growth factor mediates corneal nerve repair
-
Yu CQ, Zhang M, Matis KI, et al. Vascular endothelial growth factor mediates corneal nerve repair. Invest Ophthalmol Vis Sci. 2008;49:3870-3878.
-
(2008)
Invest Ophthalmol Vis Sci
, vol.49
, pp. 3870-3878
-
-
Yu, C.Q.1
Zhang, M.2
Matis, K.I.3
-
14
-
-
65249103986
-
Topical Bevacizumab in the treatment of corneal neovascularization: Results of a prospective, open-label, noncomparative study
-
Dastjerdi MH, Al-Arfaj KM, Nallasamy N, et al. Topical Bevacizumab in the treatment of corneal neovascularization: Results of a prospective, open-label, noncomparative study. Arch Ophthalmol. 2009;127: 381-389.
-
(2009)
Arch Ophthalmol
, vol.127
, pp. 381-389
-
-
Dastjerdi, M.H.1
Al-Arfaj, K.M.2
Nallasamy, N.3
-
15
-
-
34250365240
-
Mechanisms of adverse effects of anti-VEGF therapy for cancer
-
Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer. 2007;96:1788-1795.
-
(2007)
Br J Cancer
, vol.96
, pp. 1788-1795
-
-
Kamba, T.1
McDonald, D.M.2
-
16
-
-
66949140795
-
Understanding and managing the possible adverse effects associated with bevacizumab
-
Shord SS, Bressler LR, Tierney LA, et al. Understanding and managing the possible adverse effects associated with bevacizumab. Am J Health Syst Pharm. 2009;66:999-1013.
-
(2009)
Am J Health Syst Pharm
, vol.66
, pp. 999-1013
-
-
Shord, S.S.1
Bressler, L.R.2
Tierney, L.A.3
|